- A Prospective, Randomized Comparison of Promus Everolimus-Eluting and TAXUS Liberte Paclitaxel-Eluting Stent Systems in Patients with Coronary Artery Disease Eligible for Percutaneous Coronary Intervention: The PROMISE Study
-
Kim U, Lee CH, Jo JH, Lee HW, Choi YJ, Son JW, Lee SH, Park JS, Shin DG, Kim YJ, Jeong MH, Cho MC, Bae JH, Lee JH, Kang TS, Jung KT, Jung KH, Lee SW, Cho JH, Kim W, Hur SH, Kim KS, Park HS, Kim MH, Hwang JY, Kim DI, Kim TI
- KMID: 1777657
- J Korean Med Sci.
- 2013 Nov;28(11):1609-1614.
- doi: 10.3346/jkms.2013.28.11.1609
We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice. Patients with objective evidence of ischemia and coronary artery disease... -
- CITED
-
- Close
- SHARE
-
- Close
